NFE2L2 and cancer: Oncogenic mutations and metabolic alterations allow cancer cells to counteract the oxidative stress resulting from the accumulation of ROS by upregulating the antioxidant system mainly due the activity of transcriptional targets such as the nuclear factor (erythroid-derived 2)-like 2 (NRF2) [6] and overexpressing enzymes involved in the biosynthesis of antioxidant species, such as reduced glutathione (GSH) and cysteine [7].